Right after asserting plans previous summer season to construct its manufacturing facility in California, Sana Biotechnology has changed system. The cell and gene treatment company will now produce an 80,000 sq. foot facility in Bothell, Clean., close to its Seattle headquarters.
The new internet site is expected to final result in a lot more than $100 million in expense discounts about the prior site in the San Francisco Bay Region. The move also permits the corporation to tap into Seattle’s cell remedy production workforce, constructed up by institutions including Fred Hutchinson Most cancers Center and a slate of mobile therapy providers.
Sana will lease an existing creating and construct it out for manufacturing.
“This new facility permits us to continue on to create our interior production with no anticipated impact to the timing of our programs, and in a more cost-successful fashion,” said Sana CEO Steve Harr in a statement Wednesday asserting the new website. “Importantly, we continue on to attract the robust talent needed to execute on this eyesight and our pipeline much more broadly,” he extra.
Sana also announced that it employed the former head of mobile therapy manufacturing at Bristol Myers Squibb, Snehal Patel, who will now serve as Sana’s head of manufacturing. Patel was also beforehand site head for BMS’ Bothell cell remedy manufacturing operations, in which its “CAR T” cell treatment product Breyanzi is built.
Sana elevated $587 million in February 2021 when it went community in the greatest at any time IPO for a preclinical stage biotech business. The enterprise expects to file its to start with two investigational new drug apps this 12 months with the U.S. Meals and Drug Administration, a essential phase towards scientific trials, Sana’s vice president of finance Nicole Keith told GeekWire.
Those people programs will be for two Car T mobile remedy products and solutions for B mobile malignancies. One is an “off the shelf” item derived from donor cells and the other is a item is built to provide therapeutic cargo inside the body as a result of fusion with T cells.
Finally, the business aims to manufacture its solutions in the new creating as they enter later-stage medical development and early commercialization.
The firm no extended has ideas to construct out the formerly-declared facility, which was slated to be about double the sizing of the Bothell plant. “We have not declared unique designs for the lease in California at this time, but are assured we will be capable to uncover a remedy immediately,” claimed Keith.
The new facility will include to the developing checklist of biopharma manufacturing operations in the Seattle location. Lyell Immunopharma finished its cell manufacturing facility in Bothell very last year, and Seagen lately declared it will make a new 270,000 square foot facility in Everett. Bill Gates just lately slash the ribbon on a regional vaccine plant constructed by Inventprise, and Just-Evotec Biologics also has a new regional plant.
In addition to choosing Patel, Sana has brought on Julie Lepin as head of regulatory, security and high quality. Lepin was beforehand vice president of regulatory affairs for oncology at Amgen.